Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

NCT03455439 · clinicaltrials.gov ↗

COMPLETED

Status

552

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)

Sponsor

Bayer

Collaborators

[object Object]